Blood-based biomarkers in the anti-amyloid era of Alzheimer’s disease: clinical utility, implementation challenges, and future directions

Bo-Lin Ho, Yuan-Han Yang

Open source

DOI
10.1080/17582024.2026.2734618
Published
2026-09-26
Container
Neurodegenerative Disease Management
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/17582024.2026.2734618,
  title = {Blood-based biomarkers in the anti-amyloid era of Alzheimer’s disease: clinical utility, implementation challenges, and future directions},
  author = {Bo-Lin Ho and Yuan-Han Yang},
  year = {2026},
  journal = {Neurodegenerative Disease Management},
  doi = {10.1080/17582024.2026.2734618},
  url = {https://doi.org/10.1080/17582024.2026.2734618}
}

RIS

TY  - JOUR
TI  - Blood-based biomarkers in the anti-amyloid era of Alzheimer’s disease: clinical utility, implementation challenges, and future directions
AU  - Bo-Lin Ho
AU  - Yuan-Han Yang
PY  - 2026
JO  - Neurodegenerative Disease Management
DO  - 10.1080/17582024.2026.2734618
UR  - https://doi.org/10.1080/17582024.2026.2734618
ER  - 

APA

Ho, B., & Yang, Y. (2026). Blood-based biomarkers in the anti-amyloid era of Alzheimer’s disease: clinical utility, implementation challenges, and future directions. Neurodegenerative Disease Management. https://doi.org/10.1080/17582024.2026.2734618

Source records